Empagliflozin improves oxidative stress injury in the diabetic liver by regulating Nrf2 signaling
International Journal of Clinical and Experimental Medicine · 2025
DOI: 10.62347/ipjn8980 ↗At a glance
Journal article in International Journal of Clinical and Experimental Medicine, 2025. Written by Xiaoyun Zhang. 28 references.
Abstract (original language)
Objective
This study aimed to explore the therapeutic effect and molecular mechanism of Empagliflozin on diabetic hepatic oxidative stress injury.Methods: db/m mice were used as the control group, and db/db mice with spontaneous diabetes were randomly divided into a diabetes model group and an Empagliflozin group.The mice received continuous gavage treatment for 12 weeks.Serum was collected, and the liver tissues were fixed in 4% paraformaldehyde and frozen at -80°C.
Results
Blood glucose, total cholesterol (TC), and triglycerides (TG) of diabetic mice were significantly increased, and the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were also significantly elevated.After treatment with Empagliflozin, blood glucose, TC, and TG levels were significantly decreased, with ALT and AST also being reduced considerably.In the diabetic liver, the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were significantly decreased, and the level of malondialdehyde (MDA) was significantly increased.The expression of heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and nuclear factor erythroid 2-related factor 2 (Nrf2) were significantly decreased.Simultaneously, the expression of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) increased, and the deposition of collagen fibers was enhanced.After treatment with Empagliflozin, the liver cell structure of diabetic mice was partially restored.
Conclusion
Empagliflozin can significantly improve the metabolic disorders of blood glucose and blood lipids in diabetes mellitus and play a therapeutic role in diabetic liver injury by reducing oxidative stress in the liver, inhibiting the inflammatory response, and improving liver fibrosis.
Cite
APA
Zhang, X. (2025). Empagliflozin improves oxidative stress injury in the diabetic liver by regulating Nrf2 signaling. International Journal of Clinical and Experimental Medicine. https://doi.org/10.62347/ipjn8980
Vancouver
Zhang X. Empagliflozin improves oxidative stress injury in the diabetic liver by regulating Nrf2 signaling. International Journal of Clinical and Experimental Medicine. 2025. doi:10.62347/ipjn8980
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaoyun},
title = {Empagliflozin improves oxidative stress injury in the diabetic liver by regulating Nrf2 signaling},
journal = {International Journal of Clinical and Experimental Medicine},
year = {2025},
doi = {10.62347/ipjn8980}
}
EUVIMED